Viking Therapeutics (VKTX) announced that results from the company’s Phase 2b clinical trial of VK2809, the company’s novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis, or NASH, also referred to as metabolic dysfunction associated steatohepatitis, of MASH, will be highlighted in an oral late breaker presentation at the annual meeting of the American Association for the Study of Liver Disease, or AASLD, on Tuesday, November 19, at 11:00-11:10 a.m. Pacific Time.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Biotech Alert: Searches spiking for these stocks today
- Viking Therapeutics (VKTX) Stock Surges on Promising Treatment Pipeline
- Viking Therapeutics participates in a conference call with JPMorgan
- Eli Lilly (NYSE:LLY) Stock Falls as Competitors Report Progress
- AstraZeneca says experimental obesity pill ‘competitive,’ Bloomberg reports